Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(1.53) per share which missed the analyst consensus estimate of $(1.52) by 0.66 percent. The company reported quarterly sales of $11.871 million which beat the analyst consensus estimate of $10.802 million by 9.89 percent. This is a 337.08 percent increase over sales of $2.716 million the same period last year.